FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company focused on brain health, memory and aging, announced today that it has established its headquarters in a newly renovated facility located in Framingham, Mass. Alzheon’s new offices in Framingham will support the growth in the business, product development and clinical operations driven by clinical development of ALZ-801, an oral, first-in-class, small molecule inhibitor of amyloid formation and neurotoxicity for the treatment of Alzheimer’s disease. Alzheon is advancing ALZ-801 toward initiation of a potential pivotal clinical study in Alzheimer’s disease in the near future.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
